

Ph H 603

2748-9222

ST00 (?)

ANTIOXIDANTS IN DISEASE MECHANISMS AND THERAPY

Edited by

Helmut Sies

Institute of Physiological Chemistry
Heinrich-Heine-Universität Düsseldorf
Düsseldorf, Germany

ADVANCES IN
PHARMACOLOGY

VOLUME 38



ACADEMIC PRESS

San Diego London Boston New York Sydney Tokyo Toronto

2.F.

03662201X

Contents

Contributors xvii

Preface xxiii

PART I Natural Antioxidants

Antioxidants: The Basics—What They Are and How to Evaluate Them

Barry Halliwell

- I. Introduction 3
- II. Biologically Relevant ROS/RNS 6
- III. Proving That a Putative Antioxidant Is Important *in Vivo* 16
- References 17

Metabolism of Vitamin C in Health and Disease

Ann M. Bode

- I. Introduction and Overview 21
- II. Changes in Vitamin C Status Associated with Disease 22
- III. Mechanism of Changes in Vitamin C Status Associated with Disease 24
- IV. Evidence for Therapeutic Effectiveness of Vitamin C 35
- V. Significance and Conclusions 39
- References 40

Regulation of Human Plasma Vitamin E

Maret G. Traber

- I. Introduction 49
- II. Plasma Kinetics 50
- III. Discrimination between Tocopherols 52
- IV. Genetic Studies 54
- V. Conclusions 58
- References 59

Glutathione and Glutathione Delivery Compounds

Mary E. Anderson

- I. Glutathione 65
- II. Glutathione Delivery Compounds 70
- III. Summary 74
- References 74

α -Lipoic Acid: A Metabolic Antioxidant and Potential Redox Modulator of Transcription

Lester Packer, Sashwati Roy, and Chandan K. Sen

- I. Introduction 79
- II. Role of Lipoate in Metabolism 80
- III. Antioxidant Properties 85
- IV. NF- κ B Role in Normal and Abnormal Cell Function 91
- References 96

Antioxidant Actions of Melatonin

Russel J. Reiter

- I. Introduction 103
- II. Melatonin as a Free Radical Scavenger 104
- III. Melatonin as an Antioxidant 107
- IV. Effect of Melatonin on Enzymes Related to the Antioxidative Defense System 113
- V. Concluding Remarks 114
- References 115

Antioxidative and Metal-Chelating Effects of Polyamines

Erik Løvaas

- I. Introduction 119
- II. Chemistry and Type Reactions of Polyamines 121
- III. Antioxidative Effects of Polyamines 128
- IV. Conclusions 140
- References 141

Antioxidant and Chelating Properties of Flavonoids

Ludmila G. Korkina and Igor B. Afanas'ev

- I. Introduction 151
- II. Free Radical-Scavenging, Antioxidant, and Chelatory Activities of Flavonoids 152
- III. Prooxidant Activity of Flavonoids 156
- IV. Cytotoxic Effects of Flavonoids against Tumor Cells 157
- V. Mutagenic and Antimutagenic Properties of Flavonoids 159
- References 159

PART II Synthetic Antioxidants and Enzyme Mimics

Potential Use of Iron Chelators against Oxidative Damage

Jean-Baptiste Galey

- I. Introduction 167
- II. Iron Homeostasis 169
- III. Iron Release during Oxidative Stress 172
- IV. Iron Chelators 176
- V. Protective Effect of Iron Chelators against Oxidative Damage 191
- VI. Concluding Remarks 195
- References 196

N-Acetylcysteine: Pharmacological Considerations and Experimental and Clinical Applications

Ian A. Cotgreave

- I. Introduction 205
- II. Biopharmaceutical and Pharmacological Aspects 206
- III. General Biochemical and Cellular Effects 209
- IV. Specific Therapeutic Effects of NAC in Animals and Humans 213
- V. Summary 221
- References 221

Ebselen as a Glutathione Peroxidase Mimic and as a Scavenger of Peroxynitrite

Helmut Sies and Hiroshi Masumoto

- I. Introduction 229
- II. Synthesis of Ebselen 230
- III. Molecular Activities of Ebselen 230
- IV. Activity in Biological Model Systems 236
- V. Metabolism 238
- VI. Clinical Assessment 239
- VII. Other Selenoorganic Compounds 240
- VIII. Concluding Remarks 240
- References 241

Salen-Manganese Complexes: Combined Superoxide Dismutase/Catalase Mimics with Broad Pharmacological Efficacy

Susan R. Doctrow, Karl Huffman, Catherine B. Marcus, Wael Musleh, Annadora Bruce, Michel Baudry, and Bernard Malfroy

- I. Introduction 247
- II. Multiple Catalytic Activities of EUK-8, a Prototype SOD/Catalase Mimic 249
- III. Efficacy of EUK-8 in Experimental Models for Disease 256
- IV. Conclusions and Future Directions 264
- References 265

PART III Antioxidant Enzyme Induction and Pathophysiology

Antioxidant Drug Targeting

Anthony C. Allison

- I. Introduction 273
- II. Delivering Antioxidants to Organs or Tissues 274
- III. Targeting Antioxidants to Particular Cell Types 276
- IV. Effects of Antioxidants on Enzymes 277
- V. Reactive Oxygen Intermediates as Signal Transducers 279
- VI. Effects of Antioxidants on Transcription Factors 281
- VII. Effects of Antioxidants on Gene Expression 284
- VIII. Discussion 288
- References 289

Antioxidant-Inducible Genes

Thomas Primiano, Thomas R. Sutter, and Thomas W. Kensler

- I. Introduction 293
- II. Genes Induced by Antioxidants 294
- III. Mechanisms of Gene Induction by Antioxidants 307
- IV. Consequences of Antioxidant Gene Induction 315
- V. Future Perspectives 317
- References 317

Redox Signaling and the Control of Cell Growth and Death

Garth Powis, John R. Gasdaska, and Amanda Baker

- I. Introduction 329
- II. Cellular Redox Systems 330
- III. Redox Targets 335
- IV. Cellular Responses to Redox Changes 340
- V. Conclusion 349
- References 349

Protective Action of Nitronone-Based Free Radical Traps against Oxidative Damage to the Central Nervous System

Robert A. Floyd

- I. Introduction 361
- II. CNS Is Sensitive to Oxidative Damage 362
- III. Spin-Trapping Reactions of Nitronone-Based Free Radical Traps 363
- IV. Antioxidant Activity of PBN 364
- V. PBN Exhibits Protective Activity in Septic Shock Models 365
- VI. PBN and Related Compounds Are Neuroprotective 365
- VII. Pharmacology Studies of PBN and Related Compounds 366
- VIII. PBN Prevents LPS-Mediated NO Formation in Liver 367
- IX. NO Chemistry and Its Potential Neurotoxic Action 368
- X. Hypothesis to Explain the Neuroprotective Action of PBN 370
- References 374

Reactive Oxygen Species and Their Contribution to Pathology in Down Syndrome

Judy B. de Haan, Ernst J. Wolvetang, Francesca Cristiano, Rocco Iannello, Cecile Bladier, Michael J. Kelner, and Ismail Kola

- I. Introduction 379
- II. Sod1 and Gpx1 Expression Levels in Down Syndrome 381
- III. Premature Aging of Down Syndrome Individuals 383
- IV. Apoptosis and Down Syndrome 391
- V. Conclusion and Discussion 397
- References 398

Antioxidants, Redox-Regulated Transcription Factors, and Inflammation

Paul G. Winyard and David R. Blake

- I. Background 403
- II. Two Redox-Controlled Transcription Factors: AP-1 and NF- κ B 406
- III. ROI/RNI and NF- κ B in Human Diseases 409
- IV. Ischemic-Reperfusion Injury, Rheumatoid Arthritis, and Redox-Regulated Transcription Factors 410
- V. NF- κ B and Anti-inflammatory Drugs 411

- VI. What Is the Cellular Source of ROI Involved in NF- κ B Activation? 412
- VII. Conclusion 416
- References 416

PART IV Disease Processes

Relationships among Oxidation of Low-Density Lipoprotein, Antioxidant Protection, and Atherosclerosis

Hermann Esterbauer, Reinhold Schmidt, and Marianne Hayn

- I. Introduction 425
- II. The Low-Density Lipoprotein Oxidation Hypothesis 427
- III. Assessment of Oxidation Resistance of Low-Density Lipoprotein 431
- IV. Vitamin E Supplementation Increases Oxidation Resistance of Low-Density Lipoprotein as Judged by the Conjugated Diene Method 434
- V. Plasma Low-Density Lipoprotein Antioxidant Levels 437
- VI. Epidemiological Studies 440
- VII. Conclusion 447
- References 448

Adult Respiratory Distress Syndrome: A Radical Perspective

Samuel Louie, Barry Halliwell, and Carroll Edward Cross

- I. Introduction 457
- II. Pathobiologic Considerations 460
- III. Therapeutic Strategies 472
- IV. Conclusion 480
- References 481

Oxidative Stress in Cystic Fibrosis: Does It Occur and Does It Matter?

Albert van der Vliet, Jason P. Eiserich, Gregory P. Marelich, Barry Halliwell, and Carroll E. Cross

- I. Introduction 491
- II. Role of Oxygen-Derived Species 492

- III. Oxidative Stress and Lung Disease 494
- IV. Evidence for Oxidative Stress in Cystic Fibrosis 494
- V. The Special Case of β -Carotene Deficiency 497
- VI. Oxidative Stress at the Airway Surface 498
- VII. Potential Role of Nitric Oxide and Related Species in Cystic Fibrosis 500
- VIII. Other Considerations 503
- IX. Potential for Antioxidant Therapy 503
- X. Dilemma of Administering Aerosolized Thiols or Ascorbic Acid 504
- XI. Conclusion 505
- References 505

Oxidative Stress and Antioxidant Function in Relation to Risk for Cataract

Allen Taylor and Thomas Nowell

- I. Introduction 516
- II. Public Health Issues Regarding Cataract 517
- III. Clinical Features of Cataract 518
- IV. Oxidation, Smoking, and Cataract Formation 518
- V. Associations between Antioxidants and Cataract 519
- VI. Conclusions 531
- References 532

The Macular Pigment: A Possible Role in Protection from Age-Related Macular Degeneration

John T. Landrum, Richard A. Bone, and Mark D. Kilburn

- I. Introduction 537
- II. The Macular Pigment 538
- III. Age-Related Macular Degeneration 541
- IV. Methods 542
- V. Results 547
- VI. Discussion and Conclusions 551
- References 553

Neurological Disease

David P. R. Muller

- I. Introduction 557
- II. Antioxidant Deficiency 558

III. Increased Concentrations of Reactive Oxygen Species	563
IV. Conclusions	572
References	572

Role of Cysteine and Glutathione in HIV Infection and Cancer Cachexia: Therapeutic Intervention with N-Acetylcysteine

Wulf Dröge, Andrea Gross, Volker Hack, Ralf Kinscherf, Michael Schykowski, Michael Bockstette, Sabine Mihm, and Dagmar Galter

I. Introduction	581
II. Elevated Venous Plasma Glutamate Levels as an Early and Possibly Universal Marker for Catabolic and Precatabolic Conditions	583
III. "Push" and "Pull" Mechanisms in Catabolic and Precatabolic Processes	585
IV. Immunological Implications	589
V. Therapeutic Intervention with a Cysteine Derivative: Effects of Long-Term Treatment with N-Acetylcysteine	592
VI. Concluding Remarks	595
References	596

Role of Oxidative Stress and Antioxidant Therapy in Alcoholic and Nonalcoholic Liver Diseases

Charles S. Lieber

I. Metabolism of Ethanol	601
II. Acetaldehyde: Its Metabolism and Toxicity, Including Peroxidation	610
III. Antioxidant Therapy	611
IV. Summary	618
References	619

Antioxidant Therapy for the Prevention of Type I Diabetes

Birgit Heller, Volker Burkart, Eberhard Lampeter, and Hubert Kolb

I. Introduction	629
II. Mechanism of Reactive Oxygen Intermediates and Nitric Oxide Toxicity	630
III. Intervention Studies in Animals	632

- IV. Intervention Studies in Humans 634
- V. Concluding Remarks 635
- References 635

Photoaging of the Connective Tissue of Skin: Its Prevention and Therapy

Karin Scharffetter-Kochanek

- I. Introduction 639
- II. The Nature of Photoaging 640
- III. Role of Ultraviolet-Generated Oxygen Species in
Cutaneous Photoaging 642
- IV. Prevention and Therapy of Connective Tissue Damage 647
- References 650

Antioxidant Nutrients and Cancer Incidence and Mortality: An Epidemiologic Perspective

Susan T. Mayne

- I. Introduction 657
- II. Antioxidant Nutrients and Cancer Prevention 659
- III. Antioxidant Nutrients and Cancer Survival 666
- IV. Antioxidants and Cancer: Emerging Issues 668
- V. Conclusions and Policy Implications 670
- References 671

Index 677

Contents of Previous Volumes 693